ZA9711719B - Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis. - Google Patents

Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis.

Info

Publication number
ZA9711719B
ZA9711719B ZA9711719A ZA9711719A ZA9711719B ZA 9711719 B ZA9711719 B ZA 9711719B ZA 9711719 A ZA9711719 A ZA 9711719A ZA 9711719 A ZA9711719 A ZA 9711719A ZA 9711719 B ZA9711719 B ZA 9711719B
Authority
ZA
South Africa
Prior art keywords
dimethoxycinnamoyl
restenosis
medicament
prevention
manufacture
Prior art date
Application number
ZA9711719A
Other languages
English (en)
Inventor
Juichi Fukuyama
Keiji Miyazawa
Shuichiro Hamano
Arao Ujiie
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25101171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9711719(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of ZA9711719B publication Critical patent/ZA9711719B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9711719A 1996-12-30 1997-12-30 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis. ZA9711719B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/774,418 US6019104A (en) 1996-12-30 1996-12-30 Method for the treatment or prevention of restenosis associated with coronary intervention

Publications (1)

Publication Number Publication Date
ZA9711719B true ZA9711719B (en) 1998-06-25

Family

ID=25101171

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9711719A ZA9711719B (en) 1996-12-30 1997-12-30 Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis.

Country Status (19)

Country Link
US (1) US6019104A (hu)
EP (1) EP0891185A2 (hu)
KR (1) KR19990087396A (hu)
CN (1) CN1220599A (hu)
AR (1) AR009446A1 (hu)
AU (1) AU7854198A (hu)
BR (1) BR9707877A (hu)
CA (1) CA2247306A1 (hu)
CZ (1) CZ251198A3 (hu)
EA (1) EA001931B1 (hu)
HU (1) HUP9904029A3 (hu)
ID (1) ID20165A (hu)
IL (1) IL125660A0 (hu)
NO (1) NO983947D0 (hu)
NZ (1) NZ331338A (hu)
PE (1) PE27399A1 (hu)
TR (1) TR199801698T1 (hu)
WO (1) WO1998029104A2 (hu)
ZA (1) ZA9711719B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4583597B2 (ja) * 1998-05-05 2010-11-17 ボストン サイエンティフィック リミテッド 末端が滑らかなステント
CA2361581A1 (en) * 1999-02-03 2000-08-10 Smithkline Beecham Corporation Method for the prevention or reduction of cariovascular events associated with coronary intervention
JP2002536326A (ja) * 1999-02-03 2002-10-29 スミスクライン・ビーチャム・コーポレイション 冠状動脈インターベンションに伴う心臓血管事象の予防または軽減方法
AU2001243248A1 (en) * 2000-02-23 2001-09-03 Smith Kline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
JPS5640710B2 (hu) * 1973-01-18 1981-09-22
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤

Also Published As

Publication number Publication date
NO983947D0 (no) 1998-08-27
ID20165A (id) 1998-10-15
US6019104A (en) 2000-02-01
CN1220599A (zh) 1999-06-23
HUP9904029A3 (en) 2000-11-28
NZ331338A (en) 2000-12-22
BR9707877A (pt) 1999-07-27
EA199800781A1 (ru) 1999-12-29
PE27399A1 (es) 1999-03-31
EP0891185A2 (en) 1999-01-20
WO1998029104A2 (en) 1998-07-09
CA2247306A1 (en) 1998-07-09
EA001931B1 (ru) 2001-10-22
TR199801698T1 (xx) 1999-03-22
WO1998029104A3 (en) 1998-10-01
IL125660A0 (en) 1999-04-11
CZ251198A3 (cs) 1999-08-11
AU7854198A (en) 1998-07-31
AR009446A1 (es) 2000-04-12
KR19990087396A (ko) 1999-12-27
HUP9904029A2 (hu) 2000-05-28

Similar Documents

Publication Publication Date Title
HK1005425A1 (en) Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
HK1027280A1 (en) Plant extracts for the treatment of increased boneresorption.
IL127714A0 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic depressive bipolar disorders
EP0664690A4 (en) TWO-PIECE, RE-CLOSABLE ASSEMBLY.
HK1009814A1 (en) Five-membered heterocycles having biphenylsulfonylsubstitution, process for their prparation, their use as a medicament or diagnostic, and medicament .
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AU6682298A (en) Use of r-nsaid's for the prevention of alzheimer's disease
ZA995444B (en) A method for the treatment of staphylococcal disease.
AU3728095A (en) Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis
ZA9711719B (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis.
AU7982098A (en) Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis
AU2922792A (en) Method for treatment of a contact body for exchange of heat, moisture or the like
HUP9800334A3 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
HK1010095A1 (en) Use of 8,9-dehydroestrone for the manufacture of amedicament for the treatment of diseases caused byfree radicals.
AU3071899A (en) Use of pkc-inhibitors for the manufacture of a medicament for the treatment of asthma
WO2001019358A3 (en) Use dexrazoxane for treating psoriasis
ZA9610761B (en) Medical treatment.
IL123422A0 (en) Use of 7alpha-methyl-17alpha-ethynyl-estrane derivatives for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis
EP0622079A3 (en) Gelatinase A for the treatment of Alzheimer's disease.
YU17002A (sh) Upotreba deksrazoksana u lečenju psorijaze
ZA981918B (en) Use of 2,3,4,5-tetrahydro-1H-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
HUP0000679A3 (en) Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders